Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Moodys
Novartis
Chubb
Express Scripts
Healthtrust
Daiichi Sankyo
UBS
Harvard Business School
Deloitte

Generated: February 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,144,547

« Back to Dashboard

Summary for Patent: 9,144,547
Title:Oral dosage form for controlled drug release
Abstract: An oral dosage form comprising, (i) an erodable core, which core comprises a pharmaceutically active weak base or a pharmaceutically acceptable salt or solvate thereof; and (ii) an erodable coating surrounding said core, which coating comprises one or more openings extending substantially completely through said coating but not penetrating said core and communicating from the environment of use to said core; characterized in that release of the pharmaceutically active weak base or a pharmaceutically acceptable salt or solvate thereof from the dosage form occurs through the said opening(s) by the erosion of said erodable core and through erosion of said erodable coating under pre-determined pH conditions; a process for preparing such a dosage form and the use of such a dosage form in medicine.
Inventor(s): Li; Chi Leung (Harlow, GB), Martini; Luigi (Harlow, GB), Re; Vincenzo (Harlow, GB), Willy; Helen Anne (Harlow, GB)
Assignee: Glaxo Group Limited (Brentford, Middlesex, GB)
Application Number:12/966,323
Patent Claim Types:
see list of patent claims
Compound; Dosage form; Process;

Drugs Protected by US Patent 9,144,547

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Glaxosmithkline Llc LAMICTAL XR lamotrigine TABLET, EXTENDED RELEASE;ORAL 022115-001 May 29, 2009 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Glaxosmithkline Llc LAMICTAL XR lamotrigine TABLET, EXTENDED RELEASE;ORAL 022115-002 May 29, 2009 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Glaxosmithkline Llc LAMICTAL XR lamotrigine TABLET, EXTENDED RELEASE;ORAL 022115-003 May 29, 2009 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Glaxosmithkline Llc LAMICTAL XR lamotrigine TABLET, EXTENDED RELEASE;ORAL 022115-004 May 29, 2009 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Glaxosmithkline Llc LAMICTAL XR lamotrigine TABLET, EXTENDED RELEASE;ORAL 022115-006 Jun 21, 2011 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Glaxosmithkline Llc LAMICTAL XR lamotrigine TABLET, EXTENDED RELEASE;ORAL 022115-005 Apr 14, 2010 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 9,144,547

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0203296.9Feb 12, 2002
United Kingdom0203297.7Feb 12, 2002
United Kingdom0203298.5Feb 12, 2002

International Patents Family Members for US Patent 9,144,547

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Poland 206596 ➤ Try a Free Trial
Poland 371368 ➤ Try a Free Trial
Peru 08002003 ➤ Try a Free Trial
African Intellectual Property Organization (OAPI) 12770 ➤ Try a Free Trial
New Zealand 534152 ➤ Try a Free Trial
Norway 334453 ➤ Try a Free Trial
Norway 20043633 ➤ Try a Free Trial
Malaysia 139719 ➤ Try a Free Trial
Mexico PA04007794 ➤ Try a Free Trial
Morocco 27689 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
QuintilesIMS
Baxter
Harvard Business School
Cerilliant
Johnson and Johnson
Chubb
Accenture
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot